Chief Scientific Officer - Dr Frank Bonner

Frank joined Metabometrix as Chief Scientific Officer in June 2004.

He has a background in toxicology and drug development gained through more than twenty years experience of the pharmaceutical, contract research and biotechnology industries.

He obtained a BSc (Hons) degree in Biochemistry and a PhD in Toxicology from the University of Surrey, Guildford and joined Sterling Winthrop in 1982 to establish a pre-clinical safety testing facility. During that time, Frank was involved in early collaborative work with Professor Jeremy Nicholson to pioneer the application of NMR Spectroscopy to investigate mechanisms and detection of target organ toxicities.

Following the acquisition of Sterling by Sanofi, he became Scientific Director of the UK Research Centre in Northumberland. In 1997, he was appointed to the role of Director of Science and Technology for a major Contract Research Organisation. In 2003, Frank established an independent consultancy to the pharmaceutical and associated industries.

He is past Chairman of the British Toxicology Society, and has served on several national committees including the ABPI Research and Development Committee and Drug Safety Advisory Group.